VEGFA and cancer: Catecholamine levels are increased in cancer patients which tend to activate β-adrenoceptor signaling resulting in activation of eNOS and therefore NO release which lead to vasodilation, cellular proliferation and survival, matrix metalloproteinase synthesis, and release of proangiogenic factors, IL-6, IL-8, and VEGF.